As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and gaining a ...
Despite significant R&D investments, pharma companies often underestimate the multifaceted challenges of bringing promising treatments to market – from securing favourable reimbursement to developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results